{"id":175115,"date":"2017-05-10T05:50:32","date_gmt":"2017-05-10T05:50:32","guid":{"rendered":"http:\/\/healthmedicinet.com\/i\/roches-tecentriq-fails-trial-in-advanced-bladder-cancer\/"},"modified":"2017-05-10T05:50:32","modified_gmt":"2017-05-10T05:50:32","slug":"roches-tecentriq-fails-trial-in-advanced-bladder-cancer","status":"publish","type":"post","link":"http:\/\/healthmedicinet.com\/i\/roches-tecentriq-fails-trial-in-advanced-bladder-cancer\/","title":{"rendered":"Roche&#8217;s Tecentriq fails trial in advanced bladder cancer"},"content":{"rendered":"<p><span id=\"article-text\"><br \/>\n<span id=\"midArticle_start\" \/><\/p>\n<p><span class=\"article-prime\"><\/p>\n<p><span class=\"articleLocation\">ZURICH<\/span> Roche&#8217;s Tecentriq drug has failed a late-stage trial in people with previously treated advanced bladder cancer, the Swiss drugmaker said on Wednesday.<\/p>\n<p><\/span><span id=\"midArticle_1\" \/><\/p>\n<p>                <span class=\"article-divide first-article-divide\" \/><\/p>\n<p>The phase III IMvigor211 study that evaluated the drug, whose generic name is atezolizumab, in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with chemotherapy &#8220;did not meet its primary endpoint of overall survival compared to chemotherapy&#8221;, it said.<\/p>\n<p><span id=\"midArticle_2\" \/><\/p>\n<p>                <span class=\"article-divide second-article-divide\" \/><\/p>\n<p>&#8220;While these results are not what we had expected, we believe that Tecentriq will continue to play an important role in the treatment of people with advanced bladder cancer,&#8221; Sandra Horning, chief medical officer said. <\/p>\n<p><span id=\"midArticle_3\" \/><\/p>\n<p>                <span class=\"article-divide third-article-divide\" \/><\/p>\n<p>&#8220;We are committed to helping people with advanced bladder cancer and will discuss these data with health authorities.\u201d   <\/p>\n<p><span id=\"midArticle_4\" \/><\/p>\n<p \/>\n<p> (Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi)<\/p>\n<p><span id=\"midArticle_5\" \/><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ZURICH Roche&#8217;s Tecentriq drug has failed a late-stage trial in people with previously treated advanced bladder cancer, the Swiss drugmaker said on Wednesday. The phase III IMvigor211 study that evaluated the drug, whose generic name is atezolizumab, in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with chemotherapy <a class=\"read-more-link\" href=\"http:\/\/healthmedicinet.com\/i\/roches-tecentriq-fails-trial-in-advanced-bladder-cancer\/\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-175115","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/posts\/175115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/comments?post=175115"}],"version-history":[{"count":0,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/posts\/175115\/revisions"}],"wp:attachment":[{"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/media?parent=175115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/categories?post=175115"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/healthmedicinet.com\/i\/wp-json\/wp\/v2\/tags?post=175115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}